() () aims to build companies through early-stage, opportunistic, and diversified investments in the cannabis value chain in the US and abroad.
The Nevada-based company’s business and assets include investments in Cocoon Technology LLC, , Green Therapeutics LLC, Quality Green, Folium Biosciences, and land assets in Washington state and Michigan.
Australis was spun out from cannabis behemoth Aurora Cannabis Inc (TSE:ACB) (NYSE:ACB) in September 2018 as its US investment vehicle. Aurora is not allowed to invest in US cannabis assets due to Toronto Stock Exchange and NYSE listing rules. Australis is therefore Aurora’s arm to establish a foothold in the US, before a potential US federal legalization shift.
As part of the new strategy to scale up its award-winning brands across the US and global cannabis markets, the company is seeking a 51% interest in cash-flow-healthy ALPS - the world’s premier design, construction management, commissioning, and post-commissioning consultancy for horticultural crops such as cannabis. Australis is also seeking 100% acquisition of the outstanding membership interest in Nevada-based cannabis cultivator Green Therapeutics (GT).
But the ALPS acquisition - expected to close in late February 2021 - is central to the company’s new growth blueprint.
As a condition to the completion of the proposed transaction, Terry Booth, currently a principal of ALPS, will become CEO of Australis at closing. He will take over from Dr Duke Fu, who has been serving as Interim CEO since November 2020. At such time, Dr Fu will take on the role of COO of the company, focusing on driving organic growth.
Booth built Aurora Cannabis from a late starter to a multi-billion dollar cannabis industry leader and is a seasoned entrepreneur, capital market savvy, with a deep grasp of the requirements to be successful in the global medical and recreational markets.
Australis recently announced that it is progressing well towards the completion of its proposed acquisitions of ALPS and Green Therapeutics.
The company and ALPS have agreed to extend completion of the definitive agreements to February 22, 2021. If completed, Australis will also hold an option for the acquisition of the remaining 49% of ALPS, formerly called Aurora Larssen Projects.
The Green Therapeutics transaction is also advancing with definitive agreements being drafted to meet regulatory requirements. The acquisition of Green Therapeutics is contingent on approval by the State of Nevada's Cannabis Control Board and subsequent local approval by the Clark County Department of Business Licensing.
Australis noted that ALPS is engaged in a number of projects incorporating innovation and new intellectual property. One such project is with a Scandinavian grower of tomatoes and cucumbers under which ALPS has developed an ultra-precise environment control system, significantly improving propagation success rates and therefore economic output. ALPS retains the rights to the intellectual property developed and will be able to use this technology in the cannabis sector.
Since the Australis/ALPS transaction was announced on January 5, 2021, ALPS has signed four contracts for combined revenues in excess of $5 million with Cann Group, Australia; Aldershot Greenhouses, Canada; US-based Bluehouse Greenhouse; and US-based Vertical Harvest.
Australis said Green Therapeutics continues to turn out exceptional, high-end products. Three of the company's cultivars, sold under the GT Flowers brand, have tested for high THC potency with exceptional terpene profiles.
The high quality of these products, due to GGreen Therapeutics' science-based approach to cultivation, is reflected in GT products consistently selling out in the Nevada adult-usage space in which the company has achieved a 52% penetration rate. The firm operates an 8,000 square-foot facility.
Green Therapeutics is also in the process of operationalizing assets in Missouri and Oklahoma. The company has a manufacturing license in Oklahoma and a 25% interest in an extraction and processing license in Missouri.
Meanwhile, Australis recently touted the upbeat performance of (), in which the company holds an 18% stake. The group announced record revenues for its fiscal first quarter of 2021 ending October 31, 2020. Revenues were $5.3 million, up 144% sequentially from 4Q of FY2020 and up by 267% year-over-year.
As Australis pursues its new growth strategy, the company in recent months has taken steps to strengthen its leadership. It has formed a new board and hired Jon Paul as its new CFO. He was previously CFO at PLUS Products, a CSE-listed hemp and cannabis edibles company with operations in California and Nevada. Paul oversaw the PLUS IPO and was a key member of the team responsible for its 15-fold increase in revenue.
The company has also retained Clearview Capital Consult to assist it with its investor relations efforts. Founded by Marc Lakmaaker, former VP of IR and director of corporate development at Aurora, Clearview brings a deep understanding and network in the cannabis industry and the capital markets.
Close on acquisitions of ALPS and Green Therapeutics Positioning for recreational legalization among East Coast states Eyeing possible US federal cannabis legalization“Conversion of ALPS's substantial business development pipeline in both the cannabis and traditional horticulture sectors will provide AUSA, once the acquisition is completed, with cash flow to further fuel the execution of its capital-light expansion strategy,” Australis Interim CEO Dr Duke Fu said in a recent statement.
